Site navigation

Navigation

Macular degeneration (age-related) - pegaptanib and ranibizumab

Pegaptanib and ranibizumab for the treatment of age-related macular degeneration

Status: History
Expected date of issue: TBC
Wave: 10
Process: MTA
Topic area:
  • Eye
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: David Chandiwana
Communications manager: Phil Ranson
Project manager: Christopher Feinmann
Assessment group: Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Top


 

Provisional schedule

Consultation on draft scope by stakeholders: February 2006
Information meeting with consultees: 06 June 2006
Closing date for invited submissions / evidence submission: 01 August 2006
1st appraisal committee meeting: 18 April 2007
2nd appraisal committee meeting 14 November 2007
3rd appraisal committee meeting: 13 February 2008
Top


 

Consultees and Commentators

Consultees Commentators (no right of appeal)

Manufacturers / Sponsors

  • Novartis Pharmaceuticals Ltd (ranibizumab)
  • Pfizer Ltd (pegaptanib)

Patient / Carer Groups

  • Age Concern England
  • Counsel and Care for the Elderly
  • Macular Disease Society
  • Royal National Institute of the Blindl
  • Sense

Professional Groups

  • Collegeof Optometrists
  • Royal College of Nursing
  • RoyalCollegeof Ophthalmologists

Others

  • Department of Health
  • Welsh Assembly Government

General

  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • NHS Quality Improvement Scotland

Comparator Manufacturers

  • Novartis Ophthalmics (Verteporfin/ PDT)

Assessment Team

  • National Coordinating Centre for Health Technology Assessment
  • SouthamptonHealth Technology Assessment Centre (SHTAC)

Associated Guideline Groups

  • National Collaborating Centre Acute Care

Associated Public Health Groups

  • None

Research Groups

  • Institute of Ophthalmology, University College London

Top


 

Project history

Date Update
16 August 2004 Initial schedule provided.
25 April 2006 The manufacturer of anecotave acetate has advised us that they have withdrawn regulatory application. The Institute has therefore decided to remove this appraisal from its work programme. The appraisal of ranibizumab and pegaptanib for the treatment of age-related macular degeneration will continue as per our timelines.
25 April 2006 Final scope, final matrix of consultees, consultee and commentators, comments on draft scope and provisional matrix published.
8 November 2006 The timelines have been slightly extended following advice from the manufacturer of ranibizumab on the expected timing marketing authorisation will be received. The schedule has been updated.
18 June 2007 If you are visually impaired and wish to access a large print version or an audio version of the Appraisal Consultation document, click on the link below.
7 August 2007 The planned August 9 appraisal committee discussion of AMD is not going ahead. In response to the consultation responses received the Institute is making some revisions to the economic modelling. A second committee date will be scheduled in the autumn to discuss these revisions and the responses from consultation. It is anticipated that a second appraisal consultation document (ACD) will be released following this meeting. The Institute will also be scheduling a further committee discussion for the final appraisal determination (FAD) at a later date. Given the need for a further two meetings final guidance will not be published until next year. An update will be released on this page confirming exact dates shortly.
4 October 2007 In order to maximise the chance of being able to issue guidance in a shorter timeframe we have updated the timelines set out in our previous update posted on 7th August 2007. We will now consult on the additional analysis undertaken before the next committee meeting so that all consultee and commentator views on the analysis will be available to the committee. The next committee meeting will now be held on the 14th November. The earliest possible date for publication of the guidance is March 2008
Top


 

Key documents

This page was last updated:   27 August 2008